Skip to main content
Delfa

← All trials/NCT07850765

Completed

Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets

sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

GLP-1 agonist

Listed sites

6

Recruiting sites

-

Actual enrollment

1,260

Study population

Obesity / overweight

Eligibility highlights

-

Primary endpoints

•Food Noise Questionnaire (FNQ) score•Body Weight•Health-Related Quality of Life

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07850765
Org study IDNN9536-8879

Timeline

Milestones

Study start2026-08-28actual
Primary completion2026-08-31actual
Study completion2026-08-31actual
Study first posted2026-09-30actual
Last update posted2026-09-30actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Participants receiving semaglutide for at least 16 weeks are included for secondary database analysis.

Inclusion criteria

•Aged 18 years or older
•Currently receiving Wegovy for at least 16 weeks, who at initiation of Wegovy had either: BMI of more than or equal to (≥) 27 to less than (<) 30 kilogram per meter square (kg/m^2) with at least one weight-related comorbidity and BMI of ≥30 kg/m^2
•Not currently involved in a clinical trial for overweight or obesity

Exclusion criteria

- This is a secondary database analysis

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
6
Patient-reported / QoL
4
Other (unclassified)
2

Weight & body composition

6 endpoints
Primary/protocol endpoint

Change in Body Weight

Time frame:At data capture (Day 1)

change from baseline, improvement

Primary/protocol endpoint

Change in Body Mass Index (BMI)

Time frame:At data capture (Day 1)

change from baseline, improvement

Primary/protocol endpoint

Percent Change in Body Weight

Time frame:At data capture (Day 1)

percent change from baseline, improvement

Primary/protocol endpoint

Number of Participants with Achievement of Weight-Loss Target

Time frame:At data capture (Day 1)

threshold achievement, improvement

Primary/protocol endpoint

Number of Participants who Concern About Future Weight Gain

Time frame:At data capture (Day 1)

event count, event

Primary/protocol endpoint

Impact of Wegovy on Weight-Related Burden

Time frame:At data capture (Day 1)

descriptive

Patient-reported / QoL

4 endpoints
Primary/protocol endpoint

Change in Food Noise Questionnaire (FNQ) score

Time frame:At data capture (Day 1)

change from baseline, improvement

Primary/protocol endpoint

Health-Related Quality of Life Measured by EQ-5D-5L

Time frame:At data capture (Day 1)

descriptive

Primary/protocol endpoint

Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ)

Time frame:At data capture (Day 1)

descriptive

Primary/protocol endpoint

Number of Participant Satisfaction With Wegovy

Time frame:At data capture (Day 1)

event count, event

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Health Status Measured by EQ Visual Analogue Scale (EQ-VAS)

Time frame:At data capture (Day 1)

categorical status, descriptive

Primary/protocol endpoint/low confidence

Impact of Wegovy on Daily Life and Health Behaviours

Time frame:At data capture (Day 1)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateNovember 5, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.